Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

Archives of General Psychiatry

Volumn 56, Issue 3, 1999, Pages 241-247

  Robinson, Delbert ^a,b   Woerner, Margaret G ^a,b   Alvir, Jose Ma J ^a,b   Bilder, Robert ^a,b   Goldman, Robert ^a,b   Geisler, Stephen ^a,b   Koreen, Amy ^e   Sheitman, Brian ^c   Chakos, Miranda ^c   Mayerhoff, David ^d   Lieberman, Jeffrey A ^c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^e Hillside Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LITHIUM; LORAZEPAM; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; PROPRANOLOL;

ADULT; AKATHISIA; ARTICLE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RELAPSE; SCHIZOIDISM; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 13044268459     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.3.241     Document Type: Article

References (40)

1. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993;50:369-376.
2. Wing JK. Five-year outcome in early schizophrenia. Proc R Soc Med. 1966;59: 17-18.
3. Bland RC, Newman SC, Orn H. Schizophrenia: lifetime co-morbidity in a community sample. Acta Psychiatr Scand. 1987;75:383-391.
4. Macmillan JF, Gold A, Crow TJ, Johnson AL, Johnstone EC. Expressed emotion and relapse. Br J Psychiatry. 1986;148:133-143.
5. Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study V: one-year follow-up. Br J Psychiatry. 1988;152:470-476.
6. McGlashan TH. A selective review of recent North American long-term follow up studies of schizophrenia. Schizophr Bull. 1988;14:515-542.
7. Rabiner CJ, Wegner JT, Kare JM. Outcome study of first-episode psychosis, I: relapse rates after 1 year. Am J Psychiatry. 1986;143:1155-1158.
8. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry. 1982;39:70-73.
9. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51:273-279.
10. Crow TJ, Macmillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry. 1986;148:120-127.
11. Geddes J, Mercer G, Frith CD, MacMillan F, Owens DGC, Johnstone EC. Prediction of outcome following a first episode of schizophrenia: a follow-up study of Northwick Park first episode study subjects. Br J Psychiatry. 1994;165:664-668.
12. Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study VIII: five-year follow-up: clinical and psychosocial findings. Br J Psychiatry. 1992;161:496-500.
13. Rajkumar S, Thara R. Factors affecting relapse in schizophrenia. Schizophr Res. 1989;2:403-409.
14. Leff J, Wig NN, Bedi H, Menon DK, Kuipers L, Korten A, Ernberg G, Day R, Sartorius N, Jablensky A. Relatives' expressed emotion and the course of schizophrenia in Candigarh: a two-year follow-up of a first-contact sample. Br J Psychiatry. 1990;156:351-356.
15. Zhang M, Wang M, Li J, Phillips MR. Randomised-control trial of family intervention for 78 first-episode male schizophrenia patients: an 18-month study in Suzhou, Jiangsu. Br J Psychiatry. 1994;165(suppl 24):96-102.
16. Lieberman JA, Jody D, Alvir JM, Ashtari M, Levy D, Bogerts B, Degreef G, Mayerhoff D, Cooper T. Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia: prevalence and clinical correlates. Arch Gen Psychiatry. 1993;50:357-368.
17. Lieberman JA, Alvir JM, Woerner M, Degreef G, Bilder R, Ashtari M, Bogerts B, Mayerhoff DI, Loebel A, Levy D, Hinrichsen G, Szymanski S, Chakos M, Borenstein M, Kane JM. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophr Bull 1992;18:351-371.
18. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders. New York, NY: New York Biometrics Research Division; 1977.
19. Endicott J, Spitzer RL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry. 1978;35:837-844.
20. Spitzer RL, Endicott J. Schedule for Affective Disorders and Schizophrenia - Change Version. 3rd ed. New York: New York State Psychiatric Institute; 1978.
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Government Printing office; 1976:217-222. Department of Health, Education and Welfare publication ABM 76-338.
22. Andreasen NC, Olsen S. Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry. 1982;39:789-794.
23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
24. Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology. 1979;64:171-179.
25. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8:470-484.
26. McNeil TF, Cantor-Graae E, Sjöström K. Obstetric complications as antecedents of schizophrenia: empirical effects of using different obstetric complication scales. J Psychiatr Res. 1994;28:519-530.
27. Bilder RM, Bogerts B, Ashtari M, Wu H, Alvir JM, Jody D, Reiter G, Bell L, Lieberman JA. Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr Res. 1995;17:47-58.
28. Ashtari M, Zito JL, Gold BI, Lieberman JA, Borenstein MT, Herman PG. Computerized volume measurement of brain structure. Invest Radiol. 1990;25:798-805.
29. Degreef G, Ashtari M, Bogerts B, Bilder RM, Jody DN, Alvir JMJ, Lieberman JA. Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. Arch Gen Psychiatry. 1992; 49:531-537.
30. Chakos MH, Lieberman JA, Bilder RM, Lerner G, Bogerts B, Degreef G, Wu H, Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry. 1994;151:1430-1436.
31. Degreef G, Lantos G, Bogerts B, Ashtari M, Lieberman J. Abnormalities of the septum pellucidum on MR scans in first-episode schizophrenic patients. AJNR Am J Neuroradiol. 1992;13:835-840.
32. Koreen AR, Lieberman J, Alvir J, Mayerhoff D, Loebel A, Chakos M, Amin F, Cooper T. Plasma homovanillic acid levels in first-episode schizophrenia: psychopathology and treatment response. Arch Gen Psychiatry. 1994;51:132-138.
33. Endicott J, Cohen J, Nee J, Fleiss J, Sarantakos S. Hamilton Depression Rating Scale: extracted from regular and change versions of the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry. 1981;38:98-103.
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
35. American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 1997;154(suppl 4):1-63.
36. Gittelman-Klein R, Klein DF. Premorbid asocial adjustment and prognosis in schizophrenia. J Psychiatr Res. 1969;7:35-53.
37. Szymanski S, Lieberman JA, Alvir JMJ, Mayerhoff D, Loebel A, Geisler S, Chakos M, Koreen A, Jody D, Kane JM, Woerner M, Cooper T. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry. 1995;152:698-703.
38. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JMJ, Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57:5-9.
39. Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, Woerner M. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14(suppl):13S-21S.
40. Bogerts B, Ashtari M, Degreef G, Alvir JM, Bilder RM, Lieberman JA. Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res. 1990;35:1-13.